- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.10. | Notable Labs meldet Insolvenz an, Vorstand tritt zurück | 3 | Investing.com Deutsch | ||
| 15.10. | Notable Labs files for bankruptcy, board resigns | 2 | Investing.com | ||
| 15.10. | Notable Labs files for bankruptcy, ending ambitions for Boehringer cancer drug | 4 | FierceBiotech | ||
| NOTABLE LABS Aktie jetzt für 0€ handeln | |||||
| 15.10. | Notable Labs, Ltd. - 8-K, Current Report | - | SEC Filings | ||
| 10.10. | Notable Labs-Aktie erreicht 52-Wochen-Tief bei 0,38 US-Dollar | 1 | Investing.com Deutsch | ||
| 02.10. | Notable Labs stock touches 52-week low at $0.4 amid sharp annual decline | 3 | Investing.com | ||
| 02.10. | Notable Labs-Aktie erreicht 52-Wochen-Tief bei 0,4 US-Dollar | - | Investing.com Deutsch | ||
| 20.09. | Notable Labs-Aktie erreicht 52-Wochen-Tief bei 0,44 US-Dollar | 1 | Investing.com Deutsch | ||
| 20.09. | Notable Labs stock touches 52-week low at $0.44 amid market challenges | 1 | Investing.com | ||
| 20.09. | Notable Labs-Aktie unter Druck: Aussichten für Volasertib trüben sich ein - JMP | 1 | Investing.com Deutsch | ||
| 20.09. | Notable Labs stock under pressure as volasertib outlook dims - JMP | 1 | Investing.com | ||
| 19.09. | Notable Labs announces workforce reduction and strategic shift | 1 | Investing.com | ||
| 17.09. | Notable Labs appoints new interim CEO and restructuring officer | 1 | Investing.com | ||
| 16.09. | Notable Labs, Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.08. | Notable Labs to Present Data on September 4th at SOHO 2024 | 1 | GlobeNewswire (USA) | ||
| 26.08. | Notable Labs, Ltd. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 26.08. | Notable Labs, Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.08. | Notable Labs CEO steps down | 1 | Seeking Alpha | ||
| 26.08. | Notable Labs Announces CEO Transition | 125 | GlobeNewswire (Europe) | Thomas Bock, MD resigns as CEO; Joseph Wagner, PhD, CSO, appointed interim CEO Company affirms plan to initiate volasertib Phase 2 program in the coming months FOSTER CITY, Calif., Aug. 26, 2024 (GLOBE... ► Artikel lesen | |
| 14.08. | Notable Labs, Ltd. - 10-Q, Quarterly Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CINGULATE | 4,300 | 0,00 % | Cingulate Inc.: Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market | KANSAS CITY, Kan., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology... ► Artikel lesen | |
| GALMED | 6,500 | 0,00 % | Pre-market Movers: Portage Biotech, Veea, Intuitive Machines, Applied Therapeutics, Galmed Pharmaceuticals | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.30 A.M. ET).In the Green Portage Biotech Inc. (PRTG) is up over 179% at... ► Artikel lesen | |
| ENSYSCE BIOSCIENCES | 0,540 | -7,57 % | Ensysce Biosciences Inc.: Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial | ~ Landmark Overdose Protection Clinical Trial of PF614-MPAR ~~ Expects Early Interim Data in 1Q 2025 ~ SAN DIEGO, CA / ACCESSWIRE / November 26, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"... ► Artikel lesen | |
| IMMUNEERING | 2,000 | -4,08 % | Immuneering Corporation: Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates | - Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients - - Granted FDA Orphan Drug Designation... ► Artikel lesen | |
| GRI BIO | 0,640 | 0,00 % | GRI Bio, Inc.: GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF) | Workshop, poster and oral presentation of data given as part of the 8th Annual Antifibrotic Drug Development (AFDD) Summit Data demonstrate that NKT cells are activated in airways in IPF patients... ► Artikel lesen | |
| QIAGEN | 41,475 | -0,48 % | QIAGEN N.V.: QIAGEN führt neuartige Tools zur Anpassung von digitalen PCR-Assays und NGS-Panels für die mikrobielle Analyse ein | QIAGEN führt das erste Design-Tool für individuell anpassbare digitale PCR-Assays im Markt ein, ausgestattet mit fortschrittlichen Design-Algorithmen für verschiedene mikrobielle Anwendungen und kundenspezifische... ► Artikel lesen | |
| EVOTEC | 8,585 | -3,86 % | wO Börsenlounge: Amazon | Hugo Boss | Evotec - nach Chipotle explodiert ein ganz neuer Wert! | Die Erfolgsgeschichte von Chipotle Mexican Grill ist zuletzt etwas ins Stocken geraten. Dafür springt ein neuer Wert in die Bresche. Seit Jahresanfang legt die Aktie um 200 Prozent zu und das dürfte... ► Artikel lesen | |
| JANUX THERAPEUTICS | 62,97 | +56,88 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| BIONTECH | 111,20 | -0,36 % | Evotec, Vidac Pharma, BioNTech - Krebsforschung: Die Goldgrube im Depot | Investitionen in Aktiengesellschaften, die im Bereich der Onkologieforschung tätig sind, bieten vielversprechende Renditechancen und langfristige Stabilität. Der Onkologiemarkt gehört zu den wachstumsstärksten... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,335 | -3,17 % | Recursion Pharmaceuticals, Inc.: Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma | First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesizedREC-1245... ► Artikel lesen | |
| CITIUS ONCOLOGY | 1,510 | +48,04 % | Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer Patients ... | Study, in patients with solid tumors focusing on gynecological malignant tumors such as ovarian, endometrial, and cervical, nearing completion with three remaining subjects to be enrolled27%... ► Artikel lesen | |
| VERVE THERAPEUTICS | 7,320 | +2,59 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,870 | +0,91 % | Biotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge | ||
| GUBRA | 91,80 | -5,94 % | AKTIONÄR-Depotwert Gubra: Nächstes Kaufsignal - neue Rekorde in Sicht | Die Bullen bleiben beim AKTIONÄR-Depotwert Gubra am Drücker. Zum Start in die neue Handelswoche strebt die Aktie des dänischen Wirkstoffforschers an der Heimatbörse in Kopenhagen auf ein neues Verlaufshoch... ► Artikel lesen | |
| SENTI BIOSCIENCES | 7,090 | -29,87 % | Senti Biosciences, Inc.: Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory ... | - 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile - - Dose escalation is continuing with additional... ► Artikel lesen |
Das Unternehmen NOTABLE LABS LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,04 % bei einem Aktienkurs von 0,248 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NOTABLE LABS LTD finden Sie auf Wallstreet Online.
